GERON CORP

GERN
About the company

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.

Country: United StatesPrice: $0.97Market Cap: $623.0M

Investment snapshot

0%positive consensus
Scored 1d ago

Positive

0

BUY / PASS

Neutral / negative

2 / 14

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Key risk

No clean pass — all 16 investors flag at least one profitability criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #2049 (Top 66.2%)FAILFAILFAILFAILFAILFAILFAILFAILFAILNEUTRALFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

Annual history · FY 2025 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30 · TTM ended 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

TTM ended 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-02

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-02

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · Balance sheet at 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Qualitative assessment

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-02

Score computed: 2026-11-14

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-02

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Profitability0% pass✓ 1✗ 34▾

      No clean pass — all 16 investors flag at least one profitability criterion

      Positive EPS (10 years)0/27 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)1/27 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)-88.5%
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)-81832.9% (latest)
      ✗BuffettStable or rising over 10 years
      Free Cash Flow Proxy$-174.6M
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROE-21.1%
      ✗Lynch> 15%
      EBIT / Enterprise Value-4.8%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-4.8%, ROC=-9.8%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-14.64%
      ✗PiotroskiROA > 0
      ROA Change YoY-29.40% -> -14.64% (delta: +14.76%)
      ✓PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=-19.46%, ROA=-14.64%
      ✗PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY
      ✗PiotroskiImproved YoY
      Pre-Tax Income / Revenue
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity-21.1%
      ✗Dreman> 12%
      Margin of SafetyP/B=2.8x
      ✗PabraiP/B < 1.5 or P/E < 15
      Return on Equity-57.8% (3-yr avg)
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency1/17 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue
      ✗Ackman>= 15%
      Net Income / Shareholders Equity-21.1%
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend
      ✗TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trend
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization-7.68%; #4062/6340 (top 64.1%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets
      ✗AsnessTop 30% of eligible cross-section
      Net income / positive book equity-21.10%; #3715/5226 (top 71.1%)
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-0.2031; #4248/5884 (top 72.2%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years0/10 years positive
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Valuation0% pass✓ 1✗ 27▾

      No clean pass — all 13 investors flag at least one valuation criterion

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio2.8x
      ✗Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise Value-4.8%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-4.8%, ROC=-9.8%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      Price / Book Value per Share2.8x
      ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
      Valuation ReasonablenessOE Yield=-13.4%
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF Yield
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical AverageP/B=2.8x
      ✗MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Price / FCF per Share
      ✗Ackman<= 25
      Price vs. Trailing Low102% of trailing low ($0.95)
      ✓Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization-7.68%; #4062/6340 (top 64.1%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization+0.3639; #3416/6449 (top 53.0%)
      ✗AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per Share2.75x
      ✗SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change
      ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization
      ✗OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date-41.92%; #4878/6202 (top 78.7%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Cash Flow0% pass✗ 12▾

      All 10 investors flag GERN's cash flow

      Free Cash Flow Proxy$-174.6M
      ✗BuffettPositive and growing
      FCF Positive and Growing$-219.3M
      ✗LynchPositive and growing
      Operating Cash Flow$-111.0M
      ✗PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=-19.46%, ROA=-14.64%
      ✗PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      P/E or FCF Yield
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive1/18 years FCF positive
      ✗MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap
      ✗Ackman>= 4%
      Price / FCF per Share
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency1/20 years positive
      ✗SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization
      ✗OshaughnessyTop 10% of eligible cross-section
    • Growth0% pass✗ 13▾

      All 8 investors flag GERN's growth

      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue Growth
      ✗LynchInventory growth < Revenue growth
      EPS Growth Direction
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency1/17 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth-60.2%
      ✗Ackman>= 5%
      Positive EPS Growth Frequency
      ✗AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trend
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR
      ✗SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
    • Verdicts0% pass✗ 15▾

      Split decision: 14 FAIL · 2 NEUTRAL

      Overall verdict
      ✗GrahamFAIL (2/9)✗BuffettFAIL (0/9)✗LynchFAIL (0/7)✗GreenblattRank #2049✗PiotroskiFAIL (F-Score 1)✗DremanFAIL (2/11)✗MungerFAIL (0/4)✗PabraiFAIL (0/3)✗AkreFAIL (0/6)✗MarksFAIL (0/5)✗AckmanFAIL (1/9)✗TempletonFAIL (3/8)✗SleepFAIL (0/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (0/6)✗SchlossFAIL (2/7)•OshaughnessyNEUTRAL (Not ranked)
    • Efficiency25% pass✓ 2✗ 9▾

      6 of 8 flag GERN's efficiency — Buffett, Greenblatt, Piotroski +3 more

      Current Ratio6.31
      ✓Graham>= 2.0
      ROIC (3-5 yr avg)-66.6%
      ✗Buffett> 10%
      ROIC - WACC-76.6%
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)-9.8%
      ✗Greenblatt> 25%
      Current Ratio Change YoY5.56 -> 4.66
      ✗PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY
      ✗PiotroskiImproved YoY
      Current Assets / Current Liabilities6.31
      ✓Dreman> 1.5
      Return on Invested Capital-7.3%
      ✗Munger> 15%
      ROIC (high and growing)FY2023: ROIC=-46.4%; FY2024: ROIC=-34.4%; FY2025: ROIC=-15.7%
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROICN/A (non-positive net income)
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)0/5 years above 12% (latest -15.7%)
      ✗SleepROIC > 12% in a majority of years
    • Debt & Leverage42% pass✓ 7✗ 8▾

      7 of 12 flag GERN's debt & leverage — Buffett, Lynch, Piotroski +4 more

      LT Debt vs Net Current AssetsLT Debt $120.4M vs NCA $394.5M
      ✓GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest CoverageD/E: 0.53, IC: -1.1x
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / Equity0.53
      ✗Lynch< 0.33
      Cash - Long-term Debt$-51.3M
      ✗LynchPositive preferred
      LT Debt / Total Assets Change19.95% -> 20.95%
      ✗PiotroskiDecreased YoY
      Current Assets / Current Liabilities6.31
      ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity0.53
      ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
      Debt Levels0.53
      ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDAIC=-1.1x, D/EBITDA=N/A
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity0.53
      ✓Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)-0.5313; #2532/4210 (top 60.1%)
      ✗AsnessTop 30% of eligible cross-section

    Business & financials

    Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Pharmaceutical Products
    SIC Sector: Chemicals & Pharmaceuticals
    Size: Small Cap($623.0M)
    Revenue: N/A
    Net Income: $83.5M+52.2% YoY

    Financial Snapshot

    Operating Margin--
    Return on Equity-37.0%
    Debt / Equity0.53
    Current Ratio4.66
    EPS (Diluted)$-0.13
    Shares Retired−5.6% / −17.3% 2y

    Shareholder Return

    Fiscal 2025

    Issued 5.6% of shares last year, 17.3% issued over two.

    Buybacks
    —
    Dividends
    —

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

    MetricTTM · 2026-09-30

    2025-10-01 – 2026-09-30

    Sources · derived quarter values

    Derived from cumulative filings: net income, operating income, ebit, interest expense, operating cash flow, depreciation amortization.

    Q3 FY 2026

    2026-07-01 – 2026-09-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, depreciation amortization.

    Q2 FY 2026

    2026-04-01 – 2026-06-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, depreciation amortization.

    Q1 FY 2026

    2026-01-01 – 2026-03-31

    Sources
    FY 2025
    Sources
    • 10-K · 2026-03-02
    FY 2024
    Sources
    • 10-K · 2026-03-02
    FY 2023
    Sources
    • 10-K · 2024-02-28
    FY 2022
    Sources
    • 10-K · 2023-03-16
    FY 2021
    Sources
    • 10-K · 2022-03-10
    Market Cap$623.0Mcurrent------$877.5Mest.$1.7Best.$1.0Best.$1.3Best.$362.6Mest.
    Revenue--$60.2M↑27%$57.5M↑17%$51.8M↑31%----$237.0K↓60%$596.0K↓57%$1.4M
    Operating Income-$32.1M↑49%$5.8M↑142%-$12.5M$158.0K↑101%-$68.6M↑61%-$173.7M↑10%-$193.9M↓40%-$138.6M↓22%-$114.0M
    Net Income-$47.8M↑40%$1.4M↑107%-$16.7M↓2%-$3.6M↑82%-$83.5M↑52%-$174.6M↑5%-$184.1M↓30%-$141.9M↓22%-$116.1M
    EPS (Diluted)--$0.00↑100%$-0.02$-0.01↑67%$-0.13↑52%$-0.27↑16%$-0.32↑14%$-0.37↓6%$-0.35
    Gross Margin—————————
    Operating Margin—9.6%↑133%-21.7%↑14%0.3%↑101%——-81832.9%↓252%-23246.6%↓184%-8183.7%
    ROE-21.1%↑34%———-37.0%↑41%-62.3%↑16%-74.3%↑58%-177.4%↓93%-91.8%
    Total Debt$120.4M↑1%$120.4M↑1%$120.1M↑1%$119.8M↑1%$119.5M↑1%$118.5M↑45%$81.9M↑60%$51.2M↑3%$49.8M
    Shareholders' Equity$226.7M↓9%$226.7M↓9%$218.6M↓16%$229.1M↓15%$225.9M↓19%$280.3M↑13%$247.9M↑210%$80.0M↓37%$126.4M
    Current Ratio6.31↑6%6.31↑6%6.92↓12%6.78↓14%4.66↓16%5.56↑76%3.16↑34%2.35↓43%4.11
    Debt / Equity0.53↑11%0.53↑11%0.55↑20%0.52↑18%0.53↑25%0.42↑28%0.33↓48%0.64↑62%0.39
    Operating Cash Flow-$90.5M↑32%$10.3M↑176%-$15.8M↑42%-$62.9M↓31%-$111.0M↑49%-$218.6M↓30%-$167.7M↓32%-$127.4M↓33%-$95.6M
    Free Cash Flow-----------$219.3M↓30%-$168.6M↓32%-$127.8M↓33%-$95.8M

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Pharmaceutical Products

    GERN vs Peers — Financial Grading

    RevenueN/A
    Net Income$83.5MBottom 25%
    ROE-37.0%Bottom 25%
    D/E0.53Median
    Op. Margin—
    Curr. Ratio4.66Top 25%
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    Merck & Co., Inc.MRK$364.3B$147.76$65.0B$18.3B34.7%0.94—1.542/95/94/70/3F-Score 41/11
    ABBOTT LABORATORIESABT$188.0B$108.52$44.3B$6.5B12.5%0.2518.2%1.583/94/92/71/3F-Score 53/11
    BRISTOL MYERS SQUIBB COBMY$129.7B$63.43$48.2B$7.1B38.2%2.4419.4%1.262/91/93/71/3F-Score 85/11
    BIO-TECHNE CorpTECH$11.4B$72.80$1.2B$73.4M3.8%—8.4%3.464/93/93/70/3F-Score 54/11
    REPLIGEN CORPRGEN$10.7B$167.79$738.3M$48.9M2.3%0.267.5%8.373/92/93/70/3F-Score 75/11
    IONIS PHARMACEUTICALS INCIONS$4.8B$29.06$943.7M$381.4M-78.0%3.60-40.4%3.833/91/91/70/3F-Score 43/11
    NEOGEN CORPNEOG$2.5B$11.23$870.4M$7.9M-0.4%0.76-2.5%3.823/91/92/70/3F-Score 64/11
    Pharvaris N.V.PHVS$2.4B$33.36—$206.4M-64.8%0.00——0/90/92/70/3F-Score 22/11